Wakamoto Pharmaceutical trades at 0.88× adjusted P/B
after sixteen consecutive years of pharma-segment losses.
Strengthen Wakamoto is an ongoing campaign to restore capital discipline at TSE: 4512. As an immediate step, we are filing a binding amendment to the Articles of Incorporation requiring the company to publish — and be measurable against — a rolling three-year medium-term plan with eight specified disclosures, including ROE, ROIC, WACC, and capital allocation policy.
Each figure links directly to the underlying exhibit and the board or capital-allocation issue it highlights.
The board approved a CEO transition partway through its current five-year plan, declaring the plan "broadly on track." We disagree. Until the company discloses what "on track" means in measurable terms, shareholders cannot verify it.
Wakamoto's current five-year plan sets revenue and ROE direction at the consolidated level — yet provides no profit target, no segment-by-segment capital deployment, no cost of capital, no segment ROIC, no required return on each capex decision, and no progress reporting against final-year targets. Shareholders have no objective basis on which to assess execution or capital efficiency.
A mid-stream CEO transition based solely on internal judgment, absent external verification, is not an acceptable governance event. If a transition is to occur, the new leadership must commit to a measurable plan with a defined responsibility horizon.
Read the full proposal text →
| № | Item | What the current plan discloses | What our proposal requires | Verification lens |
|---|---|---|---|---|
| 1 / 2 | ROE & profit targets | Revenue ¥15B and ROE 8% — but no breakdown of the operating-profit or net-profit basis on which ROE rests. | ROE, operating profit, net profit — targets and progress. | Can ROE 8% be reached after 16 consecutive years of pharma-segment losses? |
| 3 | Invested capital | Sources and uses of capital for production, R&D, and other capex are described — but the scope of invested capital, its breakdown, and the treatment of non-operating assets are not. | Invested-capital targets, breakdown, and progress. | Are non-operating assets dragging down capital efficiency? |
| 4 / 5 | Cost of capital assumptions | A statement of intent to deliver a return on capital that exceeds the cost of capital — but no WACC level, no cost-of-equity level, and no calculation method or assumptions. | WACC, cost of equity, and the assumptions used to derive them. | Given a 0.88× adjusted P/B, is profitability genuinely clearing the cost of capital? |
| 6 | Capital allocation | Approximately ¥8.4B + α capital plan, with ¥1.8B earmarked for shareholder returns, including dividends — but no reporting of progress against this target. | Targets, actuals, and progress for investment, shareholder returns, and asset disposals. | With two years of the five-year plan already elapsed, why is progress against the ¥1.8B shareholder-return target still so low? |
| 7 / 8 | Segment ROIC | Revenue targets disclosed for the pharma, healthcare, and global segments — but no segment-level invested capital, ROIC, or differential against cost of capital. | Segment-level ROIC, invested capital, calculation assumptions, and progress. | Does each business clear its cost of capital? |
Each exhibit is sourced directly from Wakamoto disclosure or independently reproducible market data. The originals — and the Japanese-language commentary — remain available for inspection.
Even after adding the after-tax unrealized gain on rental real estate, the share price trades below adjusted book value.
Cumulative segment losses are approaching ¥9.7B — close to ¥12.3B market capitalization.
The pharma segment has accumulated approximately ¥9.7B in losses over sixteen consecutive years — a figure that now approaches the company's entire market capitalization. The board's continued allocation of capital to a segment that has not earned its cost of capital warrants explicit justification.
A former CEO who led Wakamoto's restructuring identified the same concentration risk in 2002.
One possible reason why the pharmaceutical division has failed to improve its performance is that its research, development, sales, medical affairs and other functions may have become excessively focused on ophthalmic drugs. (…) In order to increase sales, the company appears to have been so closely tied to ophthalmologists that it has had no time or capacity to look elsewhere. The company now seems almost like a specialist in ophthalmic drugs, and under such circumstances I do not believe it can obtain any meaningful information from fields outside ophthalmology.
Expanding the ophthalmology business is, of course, a positive thing. (…) However, I believe that, in order to grow the company's overall performance, it is ultimately necessary to broaden the range of therapeutic areas in which the company operates. (…) Several years ago, I consulted Professor Kasuya, an adviser to the company, on this issue. As he appeared to share my view, I asked him to recommend an outstanding researcher capable of developing products in other fields. He replied that he would keep this in mind, but perhaps because my request was difficult to fulfil, it ultimately did not materialise.
I believe that strengthening research and development, together with sustained effort, is absolutely essential for this reform.
Mr. Shoichi Makita — who left the Bank of Japan to lead Wakamoto's restructuring — warned that excessive concentration on ophthalmology research, development, and sales was choking off information flow from outside the field. The same diagnosis applies today. Successive CEOs since 2011 have nonetheless reaffirmed ophthalmology as the core focus.
At the June 2024 AGM, 17 of 21 disclosed institutional voters opposed his re-election.
| № | Institution | Vote | Stated reason |
|---|---|---|---|
| 1 | Nomura AM | Against | Outside-director count below firm threshold |
| 2 | Nissay AM | 〃 | Cross-shareholdings threshold triggered |
| 3 | SMT AM | 〃 | Performance threshold |
| 4 | Nikko AM | 〃 | Performance below threshold; outside-director count below threshold; and cross-shareholdings threshold triggered |
| 5 | SMDAM | 〃 | ROE threshold, board-composition standard, and cross-shareholdings standard |
| 6 | Manulife IM | 〃 | Board composition, ROE threshold, cross-shareholdings level |
| 7 | Shinkin AM | 〃 | Cross-shareholdings standard et al. |
| 8 | Resona AM | 〃 | Board independence threshold (≥ 1/3) not met |
| 9 | Mitsubishi UFJ AM | 〃 | Cross-shareholdings, independent outside-director count, and underperformance |
| 10 | Mitsubishi UFJ Trust | 〃 | Performance (ROE), board composition, and cross-shareholdings |
| 11 | AM One | 〃 | Board-composition standard (outside directors) |
| 12 | BlackRock | 〃 | Cannot support continued tenure under sustained underperformance; calls for ≥ 1/3 independent outside directors |
| 13 | Fidelity | 〃 | Vote cast under outsourced proxy-voting policy |
| 14 | Pension Fund Association | 〃 | Performance threshold and board-composition standard triggered |
| 15 | Mizuho Trust | 〃 | Board-composition standard (outside directors) |
| 16 | Daiwa AM | 〃 | Insufficient progress in reducing cross-shareholdings |
| 17 | Amundi | 〃 | — |
| 18 | Meiji Yasuda Life | For | — |
| 19 | AXA Life | 〃 | — |
| 20 | Asahi Life | 〃 | Three consecutive years ROE < 5% triggered case-by-case review; profitability-improvement engagement and certain results were judged to have been confirmed. |
| 21 | Sumitomo Life | 〃 | — |
Three of the nine board seats — including the President, the Chairman, and one outside director — are filled by Mizuho FG alumni. Outside directors comprise one-third of the board.
- President & CEO Yuko Hirai
- Chairman Arata Igarashi
- Managing Director Kimihiko Sato
- Director Hiroyoshi Kasai
- Director Makoto Taniguchi
- Director Haruhisa Hirata
- Outside Katsuyoshi Ejima
- Outside Ikuro Kuwahara
- Outside Kana Hikawa
With Mizuho FG also serving as Wakamoto's largest creditor, this level of board representation against an economic ownership stake of only around 3% raises a legitimate question as to whether shareholder value is being prioritized.
→ See Exhibit 12 for the historical evolution of Mizuho FG board representation since 2017.
| Date / Event | Wakamoto | TOPIX Total Return | Spread |
|---|---|---|---|
| 2022.04.01 CEO appointment (base = 100) | 100 | 100 | +0 |
| 2023.03.31 FY2022 year-end | 86 | 105 | −19 |
| 2024.03.29 FY2023 year-end | 80 | 148 | −68 |
| 2025.03.31 FY2024 year-end | 112 | 145 | −33 |
| 2026.02.26 CEO transition announcement | 115 | 215 | −100 |
| 2026.03.31 Departure date / FY2025 year-end | 124 | 195 | −71 |
The rental-property portfolio's fair value represents more than one-quarter of the company's market capitalization.
A leap target with no disclosed numerator and no disclosed capital base.
| Actual | Per company disclosure | Nanahoshi calculations | |||
|---|---|---|---|---|---|
| FY3/24 | FY3/25 | FY3/29 | Change | Annualized | |
| Revenue | ¥7.7B | ¥7.8B | ¥15.0B | 1.9× | +17.8% |
| Pharma | ¥3.4B | ¥3.5B | ¥6.7B | 1.9× | +17.9% |
| Healthcare | ¥2.5B | ¥2.3B | ¥4.6B | 2.0× | +18.3% |
| Global | ¥1.7B | ¥1.8B | ¥3.5B | 2.0× | +18.3% |
| ROE | 0.9% | 0.5% | ≥ 8% | Material improvement |
— |
| Cross-shareholdings | 20% of net assets |
16% of net assets |
≤ 10% of net assets |
||
Each segment is being asked to materially exceed the trajectory of the past decade.
Realizable net cash equivalents represent nearly half of the equity market value.
Under the current five-year plan, Wakamoto announced capital allocation of ¥8.4B + α, including ¥1.8B for shareholder returns such as dividends. Two years into that five-year period, returns to shareholders appear to have reached only roughly ¥0.2B, making the pace of progress against the company's own shareholder-return target the core issue. The "net cash equivalents" calculation in Exhibit 18 adds rental real estate and cross-shareholdings (at expected post-tax sale proceeds) and cash, less interest-bearing debt.
Since the abrupt resignation of the former Chairman Mr. Kamiya on June 17, 2022.
Unless otherwise noted, share price and market capitalization data are based on the May 1, 2026 closing price of ¥353 (¥12.3B), and all financial data are as of December 2025.
These are the questions an external investor cannot answer using current Wakamoto disclosure — and that the proposed Articles amendment is designed to make answerable.
Profitability
Can ROE 8% be achieved given sixteen consecutive years of pharma-segment losses?
Capital productivity
Are non-operating assets — rental property and cross-shareholdings — depressing aggregate returns?
Hurdle rate
Is WACC disclosed, and does the implied equity cost reconcile with a 0.88× adjusted P/B?
Capital allocation
Why is progress against the ¥1.8B shareholder-return target still so low after two years of a five-year plan?
Segment discipline
Does each operating segment clear the cost of the capital deployed within it?
Capital allocation discipline and board independence are inseparable. Each item below is reflected in the voting concerns raised by institutional investors and in widely used governance frameworks.
President Yuko Hirai, Chairman Arata Igarashi, and Outside Director Katsuyoshi Ejima are Mizuho Financial Group alumni. With Mizuho FG also serving as Wakamoto's largest creditor, this level of board representation against an economic ownership stake of only around 3% raises a legitimate question as to whether medium-term planning decisions made by a board so constituted prioritize shareholder value.
Mr. Kamiya — former Chairman & CEO with more than ten years at the helm — was scheduled to assume Honorary Chairman status in June 2022, then abruptly resigned. According to press reporting, the resignation was linked to approximately ¥1.7M in alleged personal use of company funds. The company has not disclosed an investigation report or pursued accountability measures.
Cross-held securities worth ¥1.55B — equivalent to roughly 84% of the ¥1.84B contracted bank credit line — are pledged as loan collateral. The company has set a target to reduce policy shareholdings to 10% of net assets by FY3/29, but argues that "the very nature of pledged collateral assumes continued holding," resisting the reduction. Climate risk on these holdings is not disclosed.
Global pharma peers — Bayer, Novartis, Novo Nordisk — disclose annual experimental animal counts by species. Wakamoto cites adherence to 3R principles (Reduction, Refinement, Replacement) and to the 2006 MHLW notice on animal experimentation, but does not publish quantitative data, leaving Reduction unverifiable.
The Mizuho ratio has more than quadrupled over the past decade — from 7.7% to 33.3%.
| Period | Directors | Mizuho ratio | Mr. I. | Mr. E. | Mr. H. |
|---|---|---|---|---|---|
| June 2025 | 9 | 33.3% | ● | ● | ● |
| June 2024 | 10 | 30% | ● | ● | ● |
| June 2023 | 7 | 28.6% | ● | ● | |
| June 2022 | 7 | 28.6% | ● | ● | |
| June 2021 | 7 | 28.6% | ● | ● | |
| June 2020 | 7 | 28.6% | ● | ● | |
| June 2019 | 7 | 28.6% | ● | ● | |
| June 2018 | 8 | 25% | ● | ● | |
| June 2017 | 7 | 28.6% | ● | ● | |
| June 2016 | 13 | 15.4% | ● | ● | |
| June 2015 | 13 | 7.7% | ● |
We have engaged the company's board, president, principal shareholders, and relevant governance bodies on multiple occasions since January 2024.
Each item above links to the corresponding English PDF.
Each ask below maps directly to one of the disclosure or governance gaps documented above.
-
Adopt a rolling three-year medium-term plan in the Articles of Incorporation
Mandate disclosure of ROE, profit, segment ROIC, capex allocation, WACC, cost of equity, and capital allocation policy — with progress reporting against the prior plan.
-
If the targets cannot be substantiated, revise the plan
Make explicit the calculation basis and concrete pathway behind the FY3/29 ROE 8% target. If WACC-based justification is absent, reset the plan promptly.
-
Adopt DOE 8% as the floor for shareholder returns
Set a Dividend on Equity ratio that reflects a credible cost-of-equity hurdle, providing investors with a stable and credible return basis. In the absence of disclosed cost-of-equity assumptions, an 8% floor is aligned with the company's FY3/29 ROE target.
-
Sell rental real estate at fair value
An after-tax yield near 1% on rental assets whose fair value represents more than one-quarter of the company's market capitalization is not justifiable from a cost-of-capital standpoint.
-
Divest cross-shareholdings — promptly and entirely
Including those pledged to banks as collateral. From an ESG and capital-efficiency standpoint, neither holding nor pledging is defensible. If retention is unavoidable, disclose the climate-risk exposure and financed-emissions allocation associated with each holding.
-
Reset the board to a composition that can be expected to maximize shareholder value
Reduce the proportion of Mizuho FG-affiliated directors. Lift the share of independent outside directors to a level credible to international institutional voters.
-
Disclose an investigation report on the former Chairman's resignation, and pursue accountability
Establish a third-party committee if no investigation has been carried out. Pursue damages claims against responsible parties and articulate a recurrence-prevention plan.
-
Disclose annual animal-use figures by species
Match the disclosure standard already adopted by global pharma peers including Bayer, Novartis, and Novo Nordisk, enabling external verification of Reduction under the 3R framework.
-
Dissolve or restructure supplier shareholding arrangements
Cross-shareholdings conducted through supplier shareholding arrangements defeat the spirit of the Corporate Governance Code's call for cross-shareholding reduction.
We expect Wakamoto's directors to operate the company with shareholder value as their objective. If that is not achievable, taking the company private is a legitimate alternative — but only at a price that fully reflects the unrealized rental-property gain, i.e. above the 1.0× adjusted-P/B threshold.
If neither shareholder-value-oriented management nor a fairly priced delisting is possible, then directors who can lead such a course should be invited, and the incumbent board should step aside.
Exhibit 1 demonstrates that, on an adjusted basis incorporating the unrealized gain on Wakamoto's rental property portfolio, the stock trades at 0.88× book — consistent with a market view that the firm's equity is not earning its cost of capital.